BIO-TECHNE Corp (TECH) stock
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3040% above fair value
$72.80−0.02 (-0.03%)
Close on Nov 11, 2026Market cap $11.43BP/E 66.8Yield 0.44%
Bio-Techne EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Bio-Techne's EPS for the twelve months ending Sep 30, 2026 was $1.09, up 122.4% year over year. For fiscal 2026 it was $1.16, up 152.2% from the year before. Over ten years it grew 5.2% a year on average. The highest annual figure on record is $1.76 in fiscal 2023.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $1.16 | +152.2% |
| FY2025 | Jun 30, 2025 | $0.46 | -56.2% |
| FY2024 | Jun 30, 2024 | $1.05 | -40.3% |
| FY2023 | Jun 30, 2023 | $1.76 | +6.0% |
| FY2022 | Jun 30, 2022 | $1.66 | +90.8% |
| FY2021 | Jun 30, 2021 | $0.87 | -40.2% |
| FY2020 | Jun 30, 2020 | $1.46 | +135.6% |
| FY2019 | Jun 30, 2019 | $0.62 | -25.4% |
| FY2018 | Jun 30, 2018 | $0.83 | +63.1% |
| FY2017 | Jun 30, 2017 | $0.51 | -27.5% |
| FY2016 | Jun 30, 2016 | $0.70 | -3.1% |
| FY2015 | Jun 30, 2015 | $0.72 | -3.7% |
| FY2014 | Jun 30, 2014 | $0.75 | -1.6% |
| FY2013 | Jun 30, 2013 | $0.76 | +0.3% |
| FY2012 | Jun 30, 2012 | $0.76 | +0.7% |
| FY2011 | Jun 30, 2011 | $0.76 | +2.7% |
| FY2010 | Jun 30, 2010 | $0.73 | +5.8% |
| FY2009 | Jun 30, 2009 | $0.69 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $0.18 | -25.0% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $0.35 | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $0.32 | +128.6% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $0.24 | +9.1% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $0.24 | +14.3% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$0.11 | -144.0% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $0.14 | -54.8% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $0.22 | +29.4% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $0.21 | -32.3% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $0.25 | -46.8% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $0.31 | -27.9% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $0.17 | -45.2% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $0.31 | -43.6% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $0.47 | +23.7% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $0.43 | +16.2% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $0.31 | -36.7% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $0.55 | +30.2% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $0.38 | +322.2% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $0.37 | +32.1% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $0.49 | +70.4% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $0.42 | +103.6% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $0.09 | -75.7% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $0.28 | +21.7% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $0.29 | -61.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $0.21 | +124.3% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $0.37 | +252.4% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $0.23 | -20.0% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $0.76 | +571.1% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $0.09 | -17.8% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $0.10 | -60.7% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $0.29 | +121.2% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $0.11 | -65.1% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $0.11 | +7.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $0.27 | +44.6% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $0.13 | -11.9% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $0.32 | +545.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $0.10 | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $0.18 | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $0.15 | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $0.05 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?